Annette M. Staiger

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy, Chip Stewart, Andrew Dunford et al. · Nature Medicine · 2018 · 2K citations · Full text

Medicine, Hematology, Oncology +12

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Alessandro Pastore, Vindi Jurinović, Robert Kridel et al. · The Lancet Oncology · 2015 · 613 citations

Medicine, Immunology, Oncology +17

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology

David W. Scott, Rebecca L. King, Annette M. Staiger et al. · Blood · 2018 · 244 citations · Full text

Medicine, Hematology, Oncology +10

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Vindi Jurinović, Robert Kridel, Annette M. Staiger et al. · Blood · 2016 · 229 citations · Full text

Medicine, Immunology, Oncology +14

Clinical Impact of the Cell-of-Origin Classification and the <i>MYC</i> / <i>BCL2</i> Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group

Annette M. Staiger, Marita Ziepert, Heike Horn et al. · Journal of Clinical Oncology · 2017 · 219 citations

Medicine, Hematology, Oncology +15